Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: A randomised clinical trial

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1807-1811

  Jakubowicz, Daniela ^a   Froy, Oren ^b   Ahrén, Bo ^c   Boaz, Mona ^a   Landau, Zohar ^a   Bar Dayan, Yosefa ^a   Ganz, Tali ^a   Barnea, Maayan ^b   Wainstein, Julio ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Breakfast; Diabetes; GLP 1; Metabolic syndrome; Whey

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; MILK PROTEIN; PLACEBO; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG; WATER; WHEY PROTEIN; GLUCOSE BLOOD LEVEL;

AREA UNDER THE CURVE; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESPONSE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WHEY; ANTIDIABETIC ACTIVITY; BIOLOGICAL ACTIVITY; CELL ACTIVITY; AGED; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED;

AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; MALE; MIDDLE AGED; MILK PROTEINS;

EID: 84905587491     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3305-x     Document Type: Article

References (10)

1. Elahi D (1996) In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 19:278-286
2. Bonuccelli S, Muscelli E, Gastaldelli A, et al. (2009) Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab 297:E532-E537
3. Fehse F, Trautmann M, Holst JJ, et al. (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991-5997
4. Balas B, Baig MR, Watson C, et al. (2007) The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255
5. Gunnarsson PT, Winzell MS, Deacon CF, et al. (2006) Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 147:3173-3180
6. Frid AH, Nilsson M, Holst JJ, Bjorck IM (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 82:69-75
7. Gribble FM, Manley SE, Levy JC (2001) Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 24:1221-1225
8. Kitabchi AE, Kaminska E, Fisher JN, et al. (2000) Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with type 2 diabetes mellitus. Am J Med Sci 319:143-148
9. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR (2002) Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 25:1271-1276
10. Jakubowicz D, Froy O (2013) Biochemical and metabolic mechanisms by which dietary whey protein may combat obesity and type 2 diabetes. J Nutr Biochem 24:1-5